中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

间接药物性肝毒性的预防与治疗

郭津生

引用本文:
Citation:

间接药物性肝毒性的预防与治疗

DOI: 10.3969/j.issn.1001-5256.2022.08.040
基金项目: 

国家自然科学基金 (91129705)

国家自然科学基金 (81070340)

国家自然科学基金 (30570825)

利益冲突声明:作者声明不存在利益冲突。
详细信息
    通信作者:

    郭津生,guo.jinsheng@zs-hospital.sh.cn

Prevention and treatment of indirect drug-induced liver toxicity

Research funding: 

National Natural Science Foundation of China (91129705);

National Natural Science Foundation of China (81070340);

National Natural Science Foundation of China (30570825)

More Information
  • 摘要: 间接药物性肝毒性(IDLT)指一些药物的使用可诱发新的肝脏疾病或加重原有肝病病情,表型是那些潜在的肝脏疾病或易患病。IDLT可导致持续性肝损伤甚至急性肝衰竭,还可影响肿瘤或其他共存疾病的药物治疗,导致正在进行的化疗、免疫和靶向治疗暂停或终止,应引起重视和识别。本文针对几种IDLT机制及防治策略进行了阐述。

     

  • [1] HOOFNAGLE JH, EINAR S, BJ RNSSON ES. Drug-induced liver injury-types and phenotypes[J]. N Engl J Med, 2019, 381(3): 264-273. DOI: 10.1056/NEJMra1816149.
    [2] ANDRADE RJ, AITHAL GP, BJÖRNSSON ES, et al. EASL clinical practice guidelines: drug-induced liver injury[J]. J Hepatol, 2019, 70(6): 1222-1261. DOI: 10.1016/j.jhep.2019.02.014.
    [3] CHALASANI NP, MADDUR H, RUSSO MW, et al. ACG clinical guideline: Diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol, 2021, 116(5): 878-898. DOI: 10.14309/ajg.0000000000001259.
    [4] YU YC, MAO YM, CHEN CW, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury[J]. Hepatol Int, 2017, 11(3): 221-241. DOI: 10.1007/s12072-017-9793-2.
    [5] LOOMBA R, LIANG TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions[J]. Gastroenterology, 2017, 152: 1297-1309. DOI: 10.1053/j.gastro.2017.02.009.
    [6] EKPANYAPONG S, REDDY KR. Hepatitis B virus reactivation: What is the issue, and how should it be managed?[J]. Clin Liver Dis, 2020, 24(3): 317-333. DOI: 10.1016/j.cld.2020.04.002.
    [7] YAO ZH, LIAO WY, HO CC, et al. Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients[J]. Eur J Cancer, 2019, 117: 107-115. DOI: 10.1016/j.ejca.2019.05.032.
    [8] BURNS EA, MUHSEN IN, ANAND K, et al. Hepatitis B virus reactivation in cancer patients treated with immune checkpoint inhibitors[J]. J Immunother, 2021, 44(3): 132-139. DOI: 10.1097/cji.0000000000000358.
    [9] ZHANG X, ZHOU Y, CHEN C, et al. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition[J]. J Immunother Cancer, 2019, 7(1): 322. DOI: 10.1186/s40425-019-0808-5.
    [10] LEE PC, CHAO Y, CHEN MH, et al. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma[J]. J Immunother Cancer, 2020, 8(2): e001072. DOI: 10.1136/jitc-2020-001072.
    [11] YAU T, HSU C, KIM TY, et al. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis[J]. J Hepatol, 2019, 71(3): 543-552. DOI: 10.1016/j.jhep.2019.05.014.
    [12] KOKSAL AS, TOKA B, EMINLER AT, et al. HBV-related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanoma[J]. Ann Oncol, 2017, 28(12): 3103-3104. DOI: 10.1093/annonc/mdx502.
    [13] GODBERT B, PETITPAIN N, LOPEZ A, et al. Hepatitis B reactivation and immune check point inhibitors[J]. Dig Liver Dis, 2021, 53(4): 452-455. DOI: 10.1016/j.dld.2020.08.041.
    [14] PEERAPHATDIT TB, WANG J, ODENWALD MA, et al. Hepatotoxicity from immune checkpoint inhibitors: A systematic review and management recommendation[J]. Hepatology, 2020, 72(1): 315-329. DOI: 10.1002/hep.31227.
    [15] JENNINGS JJ, MANDALIYA R, NAKSHABANDI A, et al. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies[J]. Expert Opin Drug Metab Toxicol, 2019, 15(3): 231-244. DOI: 10.1080/17425255.2019.1574744.
    [16] WANG W, LIE P, GUO M, et al. Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data[J]. Int J Cancer, 2017, 141(5): 1018-1028. DOI: 10.1002/ijc.30678.
    [17] SUZMAN DL, PELOSOF L, ROSENBERG A, et al. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents[J]. Liver Int, 2018, 38(6): 976-987. DOI: 10.1111/liv.13746.
    [18] SANJEEVAIAH A, KERR T, BEG MS. Approach and management of checkpoint inhibitor-related immune hepatitis[J]. J Gastrointest Oncol, 2018, 9(1): 220-224. DOI: 10.21037/jgo.2017.08.14.
    [19] GROVER S, RAHMA OE, HASHEMI N, et al. Gastrointestinal and hepatic toxicities of checkpoint inhibitors: algorithms for management[J]. Am Soc Clin Oncol Educ Book, 2018, 38: 13-19. DOI: 10.1200/EDBK_100013.
    [20] ALLARD J, LE GUILLOU D, BEGRICHE K, et al. Drug-induced liver injury in obesity and nonalcoholic fatty liver disease[J]. Adv Pharmacol, 2019, 85: 75-107. DOI: 10.1016/bs.apha.2019.01.003.
    [21] Tamoxifen. LiverTox: Clinical and research information on drug-induced liver injury[M/OL]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012.
    [22] CATALDI M, CITRO V, RESNATI C, et al. New avenues for treatment and prevention of drug-induced steatosis and steatohepatitis: Much more than antioxidants[J]. Adv Ther, 2021, 38(5): 2094-2113. DOI: 10.1007/s12325-021-01669-y.
  • 加载中
计量
  • 文章访问数:  337
  • HTML全文浏览量:  110
  • PDF下载量:  66
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-02-21
  • 录用日期:  2022-03-22
  • 出版日期:  2022-08-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回